Ownership
Private
Employees
~50
Therapeutic Areas
Rare DiseasesNeurologyCardiovascular
Stage
Preclinical
Modalities
Small molecule

Alectos Therapeutics General Information

Lead program AL01811, a GBA2 inhibitor, licensed to Biogen for Parkinson's disease. OGA inhibitor program previously partnered with Merck has been repatriated.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Burnaby, British Columbia
Canada

Drug Pipeline

AL01811
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Alectos Therapeutics's pipeline data

Book a demo

Key Partnerships

[object Object], [object Object]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Alectos Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Alectos Therapeutics's complete valuation and funding history, request access »